Get the Stockscreener App
1.305
0.38%
-0.005
After Hours:
1.29
-0.015
-1.15%
Standard Biotools Inc Stock (LAB) Latest News
Standard BioTools Inc (LAB)’s Day in Review: Closing at 1.38, Down by -2.82 - The Dwinnex
Is Standard BioTools (NASDAQ:LAB) Using Debt Sensibly? - Simply Wall St
Standard BioTools Inc (NASDAQ: LAB): Can A Stock Be -21.71% Lower Year-To-Date And Still Be A Loser? - Marketing Sentinel
LAB’s 52-Week Rollercoaster: From $1.21 to $3.04 – What’s Next for Investors? - The InvestChronicle
Standard BioTools Inc [LAB] Records 200-Day SMA of $1.9928 - Knox Daily
SG Americas Securities LLC Acquires 34,670 Shares of Standard BioTools Inc. (NASDAQ:LAB) - Defense World
LAB’s latest rating updates from top analysts. - Knox Daily
Investing in Standard BioTools Inc (LAB) might be a great opportunity, but the stock is a bit undervalued - US Post News
Financial Metrics Unveiled: Standard BioTools Inc (LAB)’s Key Ratios in the Spotlight - The Dwinnex
Fluidigm Corporation : SINGuLAR™ Analysis Toolset 2.1 -January 29, 2014 at 06:22 pm EST - Marketscreener.com
Sequencing Reagents Market Trends Analysis Report 2025-2030, with Illumina, QIAGEN, BGI, PacBio, Oxford Nanopore Technologies, Agilent Technologies, Standard BioTools, Takara Bio & Meridian Bioscience - Yahoo Finance
Standard BioTools (NASDAQ:LAB) Stock Price Down 5.8%What's Next? - MarketBeat
Standard BioTools Inc. (NASDAQ:LAB) Shares Purchased by JPMorgan Chase & Co. - Defense World
Genomics Market to Grow by USD 5.21 Billion (2024-2028), Boosted by Rising Investments in R&D, with AI Impacting Market TrendsTechnavio - Yahoo Finance
Genomics Market to Grow by USD 5.21 Billion (2024-2028), Boosted by Rising Investments in R&D, with AI Driving Market TransformationTechnavio - Yahoo Finance
Standard BioTools (NASDAQ:LAB) Stock Price Down 8.5%Should You Sell? - MarketBeat
Things To Consider Before You Buy Standard BioTools Inc (NASDAQ: LAB) - Stocks Register
Standard BioTools (NASDAQ:LAB) Shares Gap DownHere's Why - MarketBeat
Appian, Bitfarms, Standard BioTools, and More Stocks See Action From Activist Investors - MSN
Now Is The Time To Build A Position In Standard BioTools Inc (NASDAQ:LAB) - Marketing Sentinel
Standard BioTools (NASDAQ:LAB) Trading Down 5.8%Here's What Happened - MarketBeat
Standard BioTools stock soars on Q4 revenue beat By Investing.com - Investing.com South Africa
Standard BioTools stock soars on Q4 revenue beat - Investing.com India
Standard BioTools (NASDAQ:LAB) Shares Gap UpWhat's Next? - MarketBeat
Standard BioTools stock soars on upbeat preliminary 4Q revenue By Investing.com - Investing.com Canada
Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday - Benzinga
Standard BioTools Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2024 - Marketscreener.com
Standard BioTools Reports 2024 Revenue Achievements and Plans - TipRanks
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2024 Revenue - The Manila Times
In the wake of Standard BioTools Inc.'s (NASDAQ:LAB) latest US$52m market cap drop, institutional owners may be forced to take severe actions - Simply Wall St
Standard BioTools Hits Top-End Revenue Target of $174M, Slashes Operating Costs in 2024 - StockTitan
Illumina launches pilot proteomics program with UK Biobank and biopharma collaborators to analyze 50,000 samples - PR Newswire
Standard BioTools announces CCO Jeremy Davis's departure By Investing.com - Investing.com Canada
Standard BioTools announces CCO Jeremy Davis's departure - Investing.com India
Standard BioTools Announces CCO Jeremy Davis’s Departure - TipRanks
Jane Street Group LLC Sells 60,340 Shares of Standard BioTools Inc. (NASDAQ:LAB) - Defense World
Standard BioTools SomaScan Assay Powers Key Insights into Semaglutide Treatment Published in Nature Medicine - The Manila Times
Principal Financial Group Inc. Has $43,000 Stock Position in Standard BioTools Inc. (NASDAQ:LAB) - Defense World
Standard BioTools' SomaScan Platform Breakthrough: Nature Medicine Study Reveals Semaglutide Insights - StockTitan
In the wake of Standard BioTools Inc.'s (NASDAQ:LAB) latest US$56m market cap drop, institutional owners may be forced to take severe actions - Yahoo Finance
Geode Capital Management LLC Buys 154,848 Shares of Standard BioTools Inc. (NASDAQ:LAB) - Defense World
Standard BioTools (NASDAQ:LAB) Stock Price Down 6.3%Should You Sell? - MarketBeat
Standard BioTools Inc. (NASDAQ:LAB) Shares Acquired by State Street Corp - MarketBeat
State Street Corp Purchases 1,157,984 Shares of Standard BioTools Inc. (NASDAQ:LAB) - Defense World
Standard BioTools Inc. (NASDAQ:LAB) Position Decreased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Barclays PLC Purchases 377,195 Shares of Standard BioTools Inc. (NASDAQ:LAB) - MarketBeat
Standard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Standard BioTools CEO to Present at J.P. Morgan Healthcare Conference 2024 - StockTitan
Standard BioTools (NASDAQ:LAB) Trading Down 6.8%Here's What Happened - MarketBeat
BNP Paribas Financial Markets Lowers Stock Position in Standard BioTools Inc. (NASDAQ:LAB) - Defense World
0.38%
1.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):